Iconovo Total Liabilities

Latest as of June 2026: Skr13.15 Million SEK ≈ $1.42 Million USD

Iconovo total liabilities. Based on the latest financial reports, Iconovo (ICO) has total liabilities worth Skr13.15 Million SEK (≈ $1.42 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Iconovo liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Iconovo (2015–2025)

Total liabilities of Iconovo from 2015 to 2025. This chart illustrates how Iconovo's total liabilities have evolved over time, based on quarterly financial data.

Iconovo Competitors by Total Liabilities

The table below lists competitors of Iconovo ranked by their total liabilities.

Company Country Total Liabilities
Turiya Bhd
KLSE:4359
Malaysia RM35.15 Million
Vogiatzoglou Systems S.A
AT:VOSYS
Greece €12.35 Million
Taihan Textile
KO:001070
Korea ₩66.83 Billion
Bravada Gold Corporation
V:BVA
Canada CA$1.39 Million
Algorae Pharmaceuticals Ltd
AU:1AI
Australia AU$111.25K
Emova Group SA
PA:ALEMV
France €42.01 Million
Ozerden Plastik Sanayi
IS:OZRDN
Turkey TL52.79 Million
Pelikan International Corp
KLSE:5231
Malaysia RM64.67 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Iconovo's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ICO total assets.

Liquidity & Leverage Metrics

Iconovo Total Liabilities Ratios Explained

Iconovo total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.09 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.08 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Iconovo's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Iconovo (2015–2025)

The table below shows the annual total liabilities of Iconovo from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 Skr13.16 Million
≈ $1.42 Million
-20.10%
2024-12-31 Skr16.47 Million
≈ $1.77 Million
+13.19%
2023-12-31 Skr14.55 Million
≈ $1.57 Million
-54.48%
2022-12-31 Skr31.97 Million
≈ $3.44 Million
+177.80%
2021-12-31 Skr11.51 Million
≈ $1.24 Million
+38.41%
2020-12-31 Skr8.32 Million
≈ $894.85K
+67.69%
2019-12-31 Skr4.96 Million
≈ $533.64K
-43.11%
2018-12-31 Skr8.72 Million
≈ $937.94K
-17.57%
2017-12-31 Skr10.57 Million
≈ $1.14 Million
-7.06%
2016-12-31 Skr11.38 Million
≈ $1.22 Million
+118.88%
2015-12-31 Skr5.20 Million
≈ $559.38K
--

About Iconovo

ST:ICO Sweden Medical Devices
Market Cap
$12.89 Million
Skr119.73 Million SEK
Market Cap Rank
#26269 Global
#545 in Sweden
Share Price
Skr1.25
Change (1 day)
-2.35%
52-Week Range
Skr0.93 - Skr1.75
All Time High
Skr95.00
About

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more